Follow-up biopsies with microvascular inflammation and persistent donor specific antibodies identify ongoing rejection in pediatric kidney transplant recipients
- 28 January 2025
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 40 (7) , 2375-2382
Abstract
Background Inadequate treatment of acute rejection (AR) in pediatric kidney transplant recipients (KTR) can contribute to early allograft failure. Serum creatinine is an insensitive marker of allograft function, especially in the pediatric population, and may not detect ongoing rejection after treatment. We evaluated the utility of follow-up biopsies to detect persistent inflammation and future episodes of rejection. Methods We performed a single-center retrospective review to identify pediatric KTR with biopsy-proven rejection and a subsequent follow-up biopsy, noting type of AR, Banff scores, serum creatinine, and presence of donor specific antibodies (DSA). Outcomes included resolution of AR, change in eGFR, DSA, persistent microvascular inflammation (MVI) and future episodes of AR. Results Twelve cases of cellular (TCMR), 9 antibody-mediated (AMR), and 8 mixed cases of AR were identified among 23 KTR. Resolution was noted in 75% with TCMR, significantly higher than AMR (22%) or mixed rejection (13%), p < 0.01. Those without resolution of AR on follow-up biopsy were more likely to have ongoing episodes of AR or graft loss (p = 0.02). Persistence of DSA and MVI was associated with lack of AR resolution (p = 0.01 and p = 0.001, respectively). Those with persistent MVI on follow-up biopsy had higher probability of future AR events or graft loss, p = 0.003. Conclusion Follow-up biopsies to assess response to AR treatment revealed that most cases of TCMR were successfully treated but that AMR and mixed rejection portend a component of chronicity and more complicated course. Identification of persistent subclinical inflammation predicts future rejection episodes, has adverse effects on graft longevity, and can inform the need for additional treatment. We advocate for implementation of a follow-up biopsy protocol and future study of non-invasive biomarkers paired with protocol biopsies. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary informationKeywords
This publication has 32 references indexed in Scilit:
- Chronic Rejection After Kidney TransplantationTransplantation, 2024
- New Creatinine- and Cystatin C–Based Equations to Estimate GFR without RaceNew England Journal of Medicine, 2021
- Impact of Subclinical Borderline Inflammation on Kidney Transplant OutcomesTransplantation Direct, 2021
- Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working GroupTransplantation, 2020
- Long-Term Outcomes of Kidney Transplantation in ChildrenPediatric Clinics of North America, 2019
- The Road to HLA Antibody Evaluation: Do Not Rely on MFIAmerican Journal of Transplantation, 2017
- Assessing Antibody Strength: Comparison of MFI, C1q, and Titer InformationAmerican Journal of Transplantation, 2015
- Quantifying Renal Allograft Loss Following Early Antibody-Mediated RejectionAmerican Journal of Transplantation, 2015
- Age-Related Kidney Transplant OutcomesJAMA Internal Medicine, 2013
- Cutoff values and data handling for solid-phase testing for antibodies to HLA: Effects on listing unacceptable antigens for thoracic organ transplantationHuman Immunology, 2012